Section Arrow
ATRA.NASDAQ
- Atara Biotherapeutics
(Financial Status)
Quotes are at least 15-min delayed:2024/05/16 01:20 EDT
Last
 0.64
+0.035 (+5.79%)
Day High 
0.67 
Prev. Close
0.605 
1-M High
0.76 
Volume 
1.00M 
Bid
0.613
Ask
0.67
Day Low
0.6 
Open
0.6 
1-M Low
0.4843 
Market Cap 
72.85M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.6 
20-SMA 0.65 
50-SMA 0.68 
52-W High 2.535 
52-W Low 0.1986 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.12/-1.25
Enterprise Value
118.54M
Balance Sheet
Book Value Per Share
-0.82
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
8.57M
Operating Revenue Per Share
0.04
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/16 01:20 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.